




Healthcare News Roundup: Biopharmaceuticals
HSMN NewsFeed - 26 Jan 2023
Cardinal Health Teams Up with Palantir to Deliver a Clinically Integrated Supply Chain Solution
Cardinal Health Teams Up with Palantir to Deliver a Clinically Integrated Supply Chain Solution
HSMN NewsFeed - 18 Jan 2023
NeuroBo Pharmaceuticals Appoints Joseph Hooker as Interim Chief Executive Officer and President
NeuroBo Pharmaceuticals Appoints Joseph Hooker as Interim Chief Executive Officer and President
HSMN NewsFeed - 12 Jan 2023
Mallinckrodt Announces Appointment of Dr. Peter Richardson, MRCP, as Chief Scientific Officer
Mallinckrodt Announces Appointment of Dr. Peter Richardson, MRCP, as Chief Scientific Officer
HSMN NewsFeed - 9 Jan 2023
Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies
Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies
HSMN NewsFeed - 6 Jan 2023
Aeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational Efficiency
Aeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational Efficiency
HSMN NewsFeed - 5 Jan 2023
Perceive Biotherapeutics Attracts $78M Series B Financing to Advance Diversified Pipeline
Perceive Biotherapeutics Attracts $78M Series B Financing to Advance Diversified Pipeline
HSMN NewsFeed - 4 Jan 2023
Monica Shaw appointed CEO of Oncopeptides - Jakob Lindberg assumes position as Chief Scientific Officer
Monica Shaw appointed CEO of Oncopeptides - Jakob Lindberg assumes position as Chief Scientific Officer
HSMN NewsFeed - 23 Dec 2022
Hyphens Pharma Licenses Winlevi(R) for All 10 ASEAN countries from Cosmo Pharmaceuticals
Hyphens Pharma Licenses Winlevi(R) for All 10 ASEAN countries from Cosmo Pharmaceuticals
HSMN NewsFeed - 21 Dec 2022
Biomica Raises $20 Million in a Financing Round to Advance its Pipeline of Microbiome-based Therapeutics
Biomica Raises $20 Million in a Financing Round to Advance its Pipeline of Microbiome-based Therapeutics
HSMN NewsFeed - 12 Dec 2022
Amgen to Host Webcast Investor Call Following Announced Acquisition of Horizon Therapeutics
Amgen to Host Webcast Investor Call Following Announced Acquisition of Horizon Therapeutics
HSMN NewsFeed - 8 Dec 2022
Dantari Debuts with $47 Million Series A to Advance Best-in-Class Targeted Medicines for Solid Tumors
Dantari Debuts with $47 Million Series A to Advance Best-in-Class Targeted Medicines for Solid Tumors